Low-dose atropine 0.01% for the treatment of childhood myopia: a pan-India multicentric retrospective study.
Br J Ophthalmol
; 108(4): 588-592, 2024 Mar 20.
Article
en En
| MEDLINE
| ID: mdl-38290805
ABSTRACT
OBJECTIVE:
The objective of this study was to assess the efficacy of low-dose atropine 0.01% in controlling myopia progression among Indian children over a 2-year period.METHODS:
This retrospective study, conducted across 20 centres in India, monitored the progression of myopia over 2 years after initiating treatment with 0.01% atropine eye drops. This included children between 6 and 14 years with baseline myopia ranging from -0.5 D to -6 D, astigmatism≤-1.5 D, anisometropia ≤ -1 D and documented myopia progression of ≥0.5 D in the year prior to starting atropine. Subjects with any other ocular pathologies were excluded.RESULTS:
A total of 732 children were included in the data analysis. The mean age of the subjects was 9.3±2.7 years. The mean myopia progression at baseline (1 year before starting atropine) was -0.75±0.31 D. The rate of myopia progression was higher in younger subjects and those with higher baseline myopic error. After initiating atropine, myopia progression significantly decreased to -0.27±0.14 D at the end of the first year and -0.24±0.15 D at the end of the second year (p<0.001). Younger children (p<0.001) and higher baseline myopia (p<0.001) was associated with greater myopia progression and poor treatment response (p<0.001 for both).CONCLUSION:
Low-dose atropine (0.01%) effectively reduces myopia progression over 2 years in Indian children.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Atropina
/
Miopía
Tipo de estudio:
Clinical_trials
/
Observational_studies
/
Risk_factors_studies
Límite:
Child
/
Humans
Idioma:
En
Revista:
Br J Ophthalmol
/
Br. j. ophthalmol
/
British journal of ophthalmology
Año:
2024
Tipo del documento:
Article
País de afiliación:
India